logo-loader
viewCello Health PLC

Block listing Interim Review

/**/ link{ color: blue }visited{ color: purple } .z{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.z{}p.br{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.bp{font-size:10.0pt;font-family: "Calibri","sans-serif";color:black}p.bs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bn{font-size:10.0pt;font-family:"Calibri","sans-serif"; color:black}p.bt{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top: 0cm; text-align: center}span.bl{font-size:10.0pt;font-family:"Calibri","sans-serif";color:black}p.bu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom: 6.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 0cm; text-align: center}span.bv{color: black; font-family: "Calibri","sans-serif"; font-size: 10.0pt; font-weight: bold} p.bw{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}p.bx{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; background:white}span.by{font-size:10.0pt;font-family: "Calibri","sans-serif";color:black}span.bf{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.bz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 13.2pt}span.be{font-size:10.5pt;color:black}table.ca{width:446.55pt;border-collapse:collapse}tr.ax{height:15.0pt}td.ba{width:208.95pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 11.0pt} span.bc{font-size:10.0pt;color:black}td.ay{width:216.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}p.cc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;line-height:normal}td.aw{width:216.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}td.at{width:8.0cm;padding:0cm 0cm 0cm 0cm;height:15.0pt}p.cd{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}span.av{font-size:10.0pt}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";}p.ce{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.ar{font-size:10.0pt;line-height:115%;color:black} table.cf{width:446.55pt;border-collapse:collapse;border:none}td.an{width:206.7pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.cg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:3.0pt;margin-right:0cm;margin-bottom: 12.1pt;margin-left:0cm;line-height:normal}span.ap{font-size:10.0pt; color:black}td.am{width:218.25pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.al{width:206.7pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ak{width:218.25pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.aj{width:166.15pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ai{width:29.75pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.ah{width:85.0pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.ag{width:24.65pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.af{width:87.0pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ch{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:3.0pt;margin-right:0cm;margin-bottom: 11.0pt;margin-left:0cm;line-height:normal}span.ad{color:black}span.ac{font-size: 10.0pt;color:black}td.ab{border:none} /**/
RNS Number : 1647A
Cello Health PLC
24 May 2019
 

24 May 2019

Cello Health plc

("Cello" or the "Company")

Additional Block Listing of Ordinary Shares

Block Listing Update

 

The Company announces that an application has been made to the London Stock Exchange for a block admission for 2,368,200 new ordinary shares of 10p each ("Ordinary Shares") to be admitted to trading on AIM.

 

These new Ordinary Shares will be issued and allotted from time to time pursuant to the exercise of existing options under the Company's PSP Option Scheme 2010, its Approved Share Option Plan 2009 and its Unapproved Scheme 2010. The new Ordinary Shares, when issued, will rank pari passu with the existing Ordinary Shares of the Company. Admission of the new Ordinary Shares is expected to occur on 31 May 2019.

 

Further to the announcement by the Company on 14 December 2018, the Company also announces that a total of 61,061 new ordinary shares of 10p each in the share capital of the Company have been issued and allotted since that date (pursuant to the Company's PSP Option Scheme 2010, its Approved Share Option Plan 2009 and its Unapproved Scheme 2010) and admitted to trading in accordance with the block listing applied for at that time (the "Block Listing"). An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below.

 

 

Enquires

Cello Health

020 7812 8460

Mark Scott, Chief Executive


Mark Bentley, Group Finance Director




Cenkos Securities

  020 7397 8900

Mark Connelly


Harry Hargreaves




Buchanan

  020 7466 5000

Mark Court


Jamie Hooper


Sophie Wills


 

 

BLOCK LISTING SIX MONTHLY RETURN

Name of applicant:

Cello Health plc

Name of scheme:

PSP Option Scheme 2010, Approved Share Option Plan 2009 and Unapproved Scheme 2010

Period of return:

From:

31 November 2018

To:

23 May 2019

Balance of unallotted securities under scheme(s) from previous return:

611,608

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2,368,200

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

(61,061)

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

2,918,747

Name of contact:

Mark Bentley, Group Finance Director

Telephone number of contact:

020 7812 8460

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRLLFFLEFISFIA

Quick facts: Cello Health PLC

Price: 128.25

Market: AIM
Market Cap: £136.12 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

4 weeks, 1 day ago

RNS

Total Voting Rights

1 week, 3 days ago

Disposal

2 weeks, 1 day ago

Interim Results

4 weeks, 1 day ago

Acquisition of ISS

on 16/8/19